167 CONVERT: Concurrent ONce-daily VErsus twice-daily RadioTherapy. A phase III randomised controlled trial for patients with limited stage small cell lung cancer (LS-SCLC) and good performance status

Small Cell Lung Cancer ◽

Controlled Trial ◽

Performance Status ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Once Daily ◽

CONVERT: Concurrent once-daily versus twice-daily radiotherapy A phase III randomised controlled trial for patients with limited stage small cell lung cancer and good performance status

Lung Cancer ◽

10.1016/s0169-5002(10)70033-7 ◽

2010 ◽

Vol 67 ◽

pp. S11 ◽

Cited By ~ 3

Author(s):

C. Faivre-Finn

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Controlled Trial ◽

Performance Status ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Once Daily ◽

CONVERT: Concurrent once-daily versus twice-daily radiotherapy – a new phase III randomised controlled trial for patients with limited-stage small cell lung cancer and good performance status

Lung Cancer ◽

10.1016/s0169-5002(09)70037-6 ◽

2009 ◽

Vol 63 ◽

pp. S12 ◽

Cited By ~ 1

Author(s):

C. Faivre-Finn ◽

S. Falk

Keyword(s):

Lung Cancer ◽

Controlled Trial ◽

Performance Status ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Once Daily ◽

Randomised Controlled ◽

New Phase

Protocol for the CONVERT trial—Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status

BMJ Open ◽

10.1136/bmjopen-2015-009849 ◽

2016 ◽

Vol 6 (1) ◽

pp. e009849 ◽

Cited By ~ 20

Author(s):

Corinne Faivre-Finn ◽

Sally Falk ◽

Linda Ashcroft ◽

Michelle Bewley ◽

Paul Lorigan ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Concurrent Chemoradiotherapy ◽

Controlled Trial ◽

Performance Status ◽

Small Cell ◽

Small Cell Lung ◽

Once Daily ◽

A two-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage Small Cell Lung Cancer (SCLC) and good performance status

http://isrctn.org/> ◽

10.1186/isrctn91927162 ◽

2012 ◽

Author(s):

Sally Falk

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Performance Status ◽

Small Cell ◽

Small Cell Lung ◽

Once Daily ◽

Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial

Annals of Oncology ◽

10.1093/annonc/mdz122 ◽

2019 ◽

Vol 30 (7) ◽

pp. 1114-1120 ◽

Cited By ~ 13

Author(s):

R.Y. Tay ◽

F. Fernández-Gutiérrez ◽

V. Foy ◽

K. Burns ◽

J. Pierce ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Prognostic Value ◽

Controlled Trial ◽

Small Cell ◽

Circulating Tumour Cells ◽

Small Cell Lung ◽

Once Daily ◽

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations

British Journal of Cancer ◽

10.1038/bjc.2016.456 ◽

2017 ◽

Vol 116 (5) ◽

pp. 568-574 ◽

Cited By ~ 79

Author(s):

J J Yang ◽

Q Zhou ◽

H H Yan ◽

X C Zhang ◽

H J Chen ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Phase Iii ◽

Egfr Mutations ◽

Small Cell Lung ◽

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(09)60737-6 ◽

2009 ◽

Vol 374 (9687) ◽

pp. 379-386 ◽

Cited By ~ 786

Author(s):

Kathy S Albain ◽

R Suzanne Swann ◽

Valerie W Rusch ◽

Andrew T Turrisi ◽

Frances A Shepherd ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Surgical Resection ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Faculty Opinions recommendation of Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718047126.793482089 ◽

2013 ◽

Author(s):

Thomas Stinchcombe

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Small Cell Lung ◽

MEDIASTinal staging of non-small cell lung cancer by endobronchial and endoscopic ultrasonography with or without additional surgical mediastinoscopy (MEDIASTrial): study protocol of a multicenter randomised controlled trial

BMC Surgery ◽

10.1186/s12893-018-0359-6 ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 12

Author(s):

Jelle E. Bousema ◽

◽

Marcel G. W. Dijkgraaf ◽

Nicole E. Papen-Botterhuis ◽

Hermien W. Schreurs ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Endoscopic Ultrasonography ◽

Study Protocol ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(16)32517-x ◽

2017 ◽

Vol 389 (10066) ◽

pp. 255-265 ◽

Cited By ~ 1731

Author(s):

Achim Rittmeyer ◽

Fabrice Barlesi ◽

Daniel Waterkamp ◽

Keunchil Park ◽

Fortunato Ciardiello ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Previously Treated ◽